Louisiana State University Health Science Center

Summary

Louisiana State University Health Science Center is a medical facility located in New Orleans, Louisiana. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Cancer, Kidney Cancer and other specialties. Louisiana State University Health Science Center is involved with conducting 254 clinical trials across 496 conditions. There are 21 research doctors associated with this hospital, such as Scott E. Delacroix, Brian C. Boulmay, Augusto C. Ochoa, and Agustin Garcia, M.D..

Top PIs

Clinical Trials running at Louisiana State University Health Science Center

Breast Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Lung Cancer

Bladder Carcinoma

Cancer

Breast cancer

Ovarian Cancer

Small Cell Lung Cancer

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.

Recruiting

2 awards

Phase 3

47 criteria

Hormone Therapy with or without Radiation

for Breast Cancer

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.

Recruiting

2 awards

Phase 3

13 criteria

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.

Recruiting

2 awards

Phase 3

19 criteria